Whole-genome sequencing of SARS-COV-2 reveals a substantially lower frequency of the UK variant than previously announced in Libya

Inas Alhudiri[1], Ahmad M. Ramadan[1], Khaled M Ibrahim[1], Mouna Eljilani[1], Adel Abdalla Aboud[1], Mohamed Ali Salem[2], Hajer Mohamed Elgheriani[2], Adam Elzagheid[1*].

[1] Genetic Engineering Department, Biotechnology Research Center, Tripoli, Libya

[2] Microbiology Department, Biotechnology Research Center, Tripoli, Libya

*Corresponding author: Professor Adam Elzagheid, email: elzagheid@btc.org.ly

Keywords: Whole-genome sequencing, SARS-COV-2, New variants, Libya

Abstract

A cluster-5 variant was detected in September 2020 in minks and humans in Denmark and currently classified as Alpha or B.1.1.7 strain. This variant presents several mutations in the spike region (S) which could increase the transmissibility of the virus 43-90% over previously circulating variants. The national center for disease control (NCDC) announced on 24th February 2021 the discovery of B.1.1.7 strain in Libya using a reverse-transcriptase PCR assay for S-gene target failure (SGTF) and reported that 25% of the tested samples were UK variant. This assay relies on the specific identification of the H69-V70 deletion in S gene which causes S gene drop out in RT-PCR; characteristic of the UK variant (B.1.1.7). This letter discusses our whole genome sequencing results of positive SARS-COV-2 samples with SGTF collected between 25th February - 4th March 2021 in Libya.

A SARS-CoV-2 spike (S) deletion H69-V70 was detected in cluster-5 variant in minks and humans in September 2020[1]. This variant presents several mutations in the spike region (S) which could increase the transmissibility of the virus 43-90% over previously circulating variants [2]. The mutations detected in the S protein are deletions at residues 69/70 and 144, and changes in N501Y, A570D, D614G, P681H, T716I, S982A and D1118H [3].

The national center for disease control (NCDC) announced on 24th February 2021 the discovery of B.1.1.7 strain in Libya using a reverse-transcriptase PCR assay (SARS-COV-2 UK RT-PCR kit, Vircell) for S-gene target failure (SGTF) and reported that 25% of the tested samples were UK variant [4]. This assay relies on the specific identification of the 69-70 deletion in S gene which causes S gene drop out in RT-PCR; characteristic of the UK variant (B.1.1.7).

Unexpectedly, our analysis showed that less than 2% of samples were B.1.1.7 strain after whole-genome sequencing (WGS) of 124 samples collected between 25th February - 4th March 2021.

Moreover, we analyzed 67 SARS-COV-2 positive samples to track UK variant using Taqpath COVID-19 RT-PCR detection assay. Median cycle threshold of these samples was 25 ± 4.6 cycles. No amplification of S gene was seen in 67% (45/67) of samples. This result was initially interpreted as the frequency of UK variant in Libya. However, these results did not coincide with the epidemiological status of the disease which showed constant disease prevalence since December 2020 with no noticeable increase [5].

We sent the extracted RNA samples for SARS-COV-2 WGS to a genomic analysis laboratory in Spain for WGS because of limited sequencing facilities in Libya. Next generation sequencing of libraries was done using Illumina platform followed by sequence mapping using Sophia MMD Software. Determination of strains, number of variants in

coding and non-coding regions, as well as evolutionary origin and geolocation was performed through Nextclade and Pangolin applications.

Our results showed that within the samples with SGTF, 80% (36/45) had deletion of ΔH69/ΔV70 as verified by sequencing. However, we detected only two samples with mutations specific to B.1.1.7. Most other samples which had H69-V70 deletion and SGTF were designated B.1.525 strain (37/67, 55%). B.1.525 lineage also contains E484K associated with South African variant and immune escape[6]. This mutation was found in 62.7% (42/67) of samples and in all B.1.525 strains. World health organization designated B.1.525 as variant of interest on 17. Mar. 2021 and has been detected in multiple countries including UK, USA, Nigeria, and few in Tunisia and Morocco[7].

COVID-19 testing in Libya is performed solely by government laboratories. The SARS-COV-2 diagnostic laboratories across Libya test approximately 3000-6000 samples per day using RT-PCR assay. Biotechnology Research Center (BTRC) is one of the major SARS-COV-2 testing centers in Libya which analyzes over 1500 samples daily received from different regions of Tripoli and western towns. The lab currently uses two assays (Taqpath & CerTest RT-PCR SARS-COV-2 detection) for routine detection of target genes: nucleocapsid (N), open reading frame (Orf1ab), and spike (S) genes.

Our data suggest that B.1.5252 is spreading widely in Libya and absence of S gene should not be routinely interpreted as B.1.1.7. This reinforces the need for whole-genome sequencing to first identify the reason for SGTF before using RT-PCR testing as a tool for surveillance for variants of concern. We also emphasize on the critical role of international collaboration especially in developing countries, for building capacity and advancing research in this time of the pandemic.

Conflict of interest

Authors declare that they have no conflict of interests.

Ethical approval

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Biotechnology Research Center Bioethics Committee.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

1 Bal A, Destras G, Gaymard A, *et al.* Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70,

France, August to December 2020. *Euro Surveill* 2021; **26**. DOI:10.2807/1560-7917.ES.2021.26.3.2100008.
2 Davies NG, Abbott S, Barnard RC, *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science (80-)* 2021; **372**: eabg3055.
3 Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations - SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology - Virological. https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563 (accessed Feb 28, 2021).
4 NCDC statements about covid-19. https://ncdc.org.ly/Ar/statements-about-covid19/ (accessed April 13, 2020).
5 WHO| COVID-19 Dashboard. 2020. https://who.sprinklr.com/ (accessed April 13, 2020).
6 Vogels CBF, Breban MI, Ott IM, *et al.* Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2. *PLoS Biol* 2021; **19**: 1–12.
7 Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed June 30, 2021).